Friday, July 10, 2026
🇺🇸 FDA

pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis

Istituto Gentili Italia

Istituto Gentili S.r.l.

Istituto Gentili S.r.l is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imp

Website Investor relations
Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT HQ
1917 Founded
121 Employees
EMA registrant Type
Programs 50 Drugs 114 Patents 0 Trial starts 50 Last 12 months
Company details
Status
Public
HQ
Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
Founded
1917
Employees
121
Programs
50
Drugs
114
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Quick answer

Istituto Gentili S.r.l is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imperfecta, cesarean section. NovaPharmaNews links 50 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (34), phase 3 (8), approved (5).

Company snapshot

Istituto Gentili Italia maintains 50 tracked programs across Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imperfecta, cesarean section, PAPA syndrome, Metastatic colorectal cancer, Cardiac arrest, Mesothelioma, Stage IV colorectal cancer, relapsing vulvar carcinoma already subjected to multiple treatments, Inflammatory Bowel Disease. Momentum

  • 50 active pipeline program(s) linked via ClinicalTrials.gov.
  • 50 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Istituto Gentili Italia. Not investment advice.

Top assets

View drugs (114) View projects (50)

Lead pipeline drugs

Active clinical programs

  • IRST204.07 Acute myeloid leukemia
    Phase 3
  • Intrarosa 6.5 mg pessary Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).
    Phase 3
  • MOTOR patients scheduled to undergo elective surgical procedures with general anesthesia
    Phase 3
  • PAPA-Can PAPA syndrome
    Phase 3

Momentum

Proprietary activity score for Istituto Gentili Italia.

0 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 0 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Istituto Gentili Italia.

  1. Clinical update

    RC 4/24 TREAT-UTI — Phase 3

  2. Clinical update

    PRINCE — Phase 3

  3. Clinical update

    IRST100.59 — Phase 2

  4. Clinical update

    5MILLE_CT1 — Phase 2

  5. Clinical update

    Wegovy solution for Diabetes Mellitus, Cardiovascul… — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Istituto Gentili Italia?

    Istituto Gentili S.r.l is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imperfecta, cesarean section. NovaPharmaNews links 50 clinical

  • Is Istituto Gentili Italia publicly traded?

    Istituto Gentili Italia appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Istituto Gentili Italia develop or market?

    We link 114 drug profile(s) where Istituto Gentili Italia is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/istituto-gentili-s-r-l#company-drugs.

  • What are the latest developments for Istituto Gentili Italia?

    In the last 12 months our linked public records show 50 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Istituto Gentili Italia focus on?

    Istituto Gentili Italia focuses on Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
83
Oncology
15
Infectious Disease
3
Immunology
2
Neurology
2
Cardiology
1
Related companies

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.